Author

Nada Farah

Nada Farah, AGPCNP-BC, OCN, is a nurse practitioner at an academic molecular tumor board clinic in Columbia, Missouri. She has worked in oncology for 16 years, beginning in outpatient medical oncology and thoracic cancer care before subspecializing in precision medicine. Farah reviews genomic profiling reports with patients to explain specific mutations and potential targeted therapies. She writes about tumor biomarkers and targeted drug therapies. She earned her doctor of nursing practice from Duke University.

Driver vs. Passenger Mutation: What’s the Difference?
Are EGFR Mutations Hereditary or Acquired?
What Are Passenger Mutations and How Do They Affect Cancer?
How Oncogenomics Enables Personalized Treatment for Cancer
What Is an NRAS Mutation and Its Role in Cancer?
What Is an ALK Mutation and How Does It Cause Cancer?
Common Melanoma Mutations and Their Role in Treatment
What Causes a HER2 Gene Mutation?
What Is a MET Mutation and How Does It Affect the Body?
What Is Comprehensive Genomic Profiling?
EGFR Mutation Types: What They Are and Why They Matter
What Is a PIK3CA Mutation and Its Role in Cancer?
ESR1 Mutations and Their Impact on Breast Cancer
BAP1 Gene: Its Role in Cancer and Genetic Risks
What Is the T790M Mutation and How Is It Treated?
The PD-L1 Gene: Role in Cancer and the Immune System
c-Myc: The Master Regulator Gene and Its Role in Cancer
TP53 Gene Mutation and Its Direct Link to Cancer
What Is an EGFR Exon 19 Deletion and How Is It Treated?
What Does a KRAS Wild-Type (wt) Result Mean?
The Link Between p53 Mutations and Breast Cancer
MALAT1 Gene: Function, Cancer Link, and Therapeutic Target
What Is TP53 Wild Type and Why Is It Important?